PBSS-1113 NCT07761533 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

29

Planned enrollment

2027-09-01

Primary-completion proxy

Executive view

NCT07761533 evaluates PBSS-1113 in Acute Myeloid Leukemia. The disclosed sponsor is Chaser Therapeutics Inc, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Composite Complete Remission (cCR) Rate in Patients with Acute Myeloid Leukemia (AML), assessed over Through study completion, an average of 1 year.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07761533 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Acute Myeloid Leukemia landscape. Drug & Asset MCP drug_fetch was queried for PBSS-1113, while Company & Deal Intelligence MCP organization_fetch was queried for Chaser Therapeutics Inc.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07761533	PBSS-1113	Phase 1/2 / Recruiting	Chaser Therapeutics Inc	China	Composite Complete Remission (cCR) Rate in Patients with Acute Myeloid Leukemia (AML) Through study completion, an average of 1 year	2027-09-01
NCT07813390	Lisaftoclax	Phase 2 / Enrolling by invitation	Guangdong General Hospital	China	Overall Response Rate After Two Cycles of HLA Therapy At the end of Cycle 2 (each cycle is 28 days; approximately Day 56)	2027-09-01
NCT07814339	Decitabine/Cedazuridine	Phase 1 / Not yet recruiting	Rutgers State University of New Jersey	Geography not reported	Phase I - Primary Endpoint 8 to 12 months	2028-06-01
NCT07809906	ORM-1153	Phase 1 / Not yet recruiting	Orum Therapeutics USA, Inc.	United States	Optimal Biological Dose(s) of ORM-1153 Approximately 24 months	2028-12-01
NCT07766850	Hydroxycarbamide	Phase 1/2 / Not yet recruiting	Region Stockholm	Sweden	1-year EFS From initiation of study treatment to the first occurrence of treatme…	2029-06-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07761533 is a Phase 1/2, recruiting study with 29 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Sequential Assignment.

The primary endpoint is “Composite Complete Remission (cCR) Rate in Patients with Acute Myeloid Leukemia (AML)” over “Through study completion, an average of 1 year.” The retrieved endpoint description is: The composite complete remission (cCR) rate is defined as the proportion of AML subjects who achieve a best overall response of complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi), or a morphological leukemia-free state (MLFS). The analysis will further evaluate the subset of patients achieving measurable residual disease (MRD) negativity within these categories (CRMRD-, CRhMRD-, or CRiMRD-)..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 29 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Acute Myeloid Leukemia. These records do not establish direct evidence for NCT07761533 unless the registration number matches.

Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study

Phase 2; n=20; Response Rate for Low/Intermediate Risk Acute Myeloid Leukemia (AML) After Induction With Vyxeos With or Without Mylotarg. = 6 Participants ; Response Rate for Low/Intermediate Risk Acute Myeloid Leukemia (AML) After Induction With Vyxeos With or Without Mylotarg. = 13 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05599360

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia

Phase 2; n=21; CR = 8 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04269213

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group

Phase 3; n=721; EFS(2-year) = 62.2 % ; EFS(2-year) = 51.2 % Source: https://pubmed.ncbi.nlm.nih.gov/42497367/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

PBSS-1113 is indexed as Small molecule drug with USP25 x USP28 biology and a global stage of Phase 2. The asset profile lists Chaser Therapeutics Inc as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Chaser Therapeutics Inc. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether PBSS-1113 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07761533
Protocol source: https://clinicaltrials.gov/study/NCT07761533
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.

PBSS-1113 in Acute Myeloid Leukemia is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Composite Complete Remission (cCR) Rate in Patients with Acute Myeloid Leukemia (AML) and 2027-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP